RECRUITING

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.

Official Title

A Long-Term Follow-up Study for Subjects Previously Treated With A Century Therapeutics Cellular Therapy Product

Quick Facts

Study Start:2024-04-29
Study Completion:2040-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05768269

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
  2. * Participants received at least one treatment with a cellular therapy product in an eligible index trial.
  3. * Participant was withdrawn, early discontinued or completed an eligible index trial.
  4. * Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Nikolaus Trede, MD
CONTACT
888-688-0644
ClinicalTeamCNTY@centurytx.com

Study Locations (Sites)

Levine Cancer Institute
Charlotte, North Carolina, 28204
United States
University of Cincinnati Medical Center
Cincinnati, Ohio, 45229
United States
Swedish Cancer Institute
Seattle, Washington, 98104
United States

Collaborators and Investigators

Sponsor: Century Therapeutics, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-29
Study Completion Date2040-03

Study Record Updates

Study Start Date2024-04-29
Study Completion Date2040-03

Terms related to this study

Keywords Provided by Researchers

  • Century Therapeutics
  • Cellular Therapy
  • Cell therapy
  • Malignancy

Additional Relevant MeSH Terms

  • Hematological Malignancy
  • Solid Tumor Malignancy